A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors
← catalyst calendarSponsored by Immuneering Corporation (industry) · IMRX — their whole pipeline →.
Phase
Phase 1/2
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
30actual
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-27 | actual | When the study began enrolling |
| Primary completion | 2025-04-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-04-30 | actual | The whole study's end, after follow-up |
| First posted | 2024-01-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Solid Tumor (Phase 1)
- Pancreas Adenocarcinoma
- Non-small Cell Lung Cancer
- Malignant Melanoma (Cutaneous)
Intervention
- Drug: IMM-6-415
Primary outcomes
what the primary-completion date above is the date OFPhase 1/2a: Adverse Events
measured From treatment initiation through 30 days following the last IMM-6-415 dose
Phase 1: Dose-Limiting Toxicities (DLT)
measured The first 21 days of study treatment
Phase 1: Recommended Phase 2 Dose (RP2D) candidate
measured Initiation of study treatment through 21 days (up to approximately 18 months)
Phase 1: Maximum Observed Plasma Concentration of IMM-6-415
measured After 9 weeks (3 Cycles) of study treatment
Phase 1: Time to Reach Maximum Observed Plasma Concentration of IMM-6-415
measured After 9 weeks (3 Cycles) of study treatment
Phase 1: Area Under Plasma Concentration (AUC) Time Curve of IMM-6-415
measured After 9 weeks (3 Cycles) of study treatment
Phase 1: Pharmacodynamic (PD) Activity of IMM-6-415 Plasma Concentrations Over Time
measured After 9 weeks (3 Cycles) of study treatment
Phase 2a: Overall Response Rate (ORR)
measured After up to 48 weeks (16 cycles) of study treatment
Permalink · IMRX's whole pipeline · Catalyst calendar · Every registered study · What changed